Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxysophocarpine is a bioactive quinolizidine alkaloid primarily extracted from the traditional Chinese medicinal herb *Sophora flavescens* (Kushen). It exhibits a broad spectrum of pharmacological activities, including neuroprotective, anti-viral, anti-convulsant, and anti-nociceptive effects. In oncology research, oxysophocarpine has demonstrated potential against hepatocellular carcinoma (HCC) by inhibiting cell proliferation, inducing apoptosis, and suppressing cell migration. Its mechanism of action involves the downregulation of the **IL-6-mediated JAK2/STAT3 signaling pathway**, which subsequently reduces the expression of **Fibrinogen-like protein 1 (FGL1)**. Since FGL1 is a major ligand for the immune checkpoint **LAG-3**, oxysophocarpine treatment sensitizes HCC cells to CD8+ T cell-mediated immunotherapy, particularly when combined with LAG-3 blockade.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxysophocarpine.